Effects of Ivacaftor (Kalydeco) Treatment Upon Insulin and Incretin Secretion in Patients With Cystic Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 27 Aug 2018 Status changed from recruiting to completed, according to results published in the American Journal of Respiratory and Critical Care Medicine.
- 12 Aug 2018 Results published in the American Journal of Respiratory and Critical Care Medicine.